STANDARD BIOTOOLS INC.
Company Stats
- Market Cap
- $290.7M
- as of Sep 30, 2026
- Shares Outstanding
- 392.6M
- Free Float
- 28.7%
Income Statement
- Revenue
- $85.3M
- Operating Income
- -$110.2M
- Net Income
- -$74.9M
- EBITDA
- -$101.0M
- Revenue Growth, 3Y
- -4.5%
- FCF Margin, 3Y Avg
- -102.3%
- FCF Margin, Worst Year
- -166.8%
Cash Flow
- Free Cash Flow
- -$82.6M
- FCF Yield
- -28.4%
- Owner FCF Yield
- -38.6%
Balance Sheet
- Cash & Equivalents
- $120.9M
Returns & Capital
- Buyback Yield, 3Y Avg
- 5.3%
- SBC, 3Y Avg
- $24.8M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $85.3M | -$82.6M | -96.9% |
| FY2024 | $91.0M | -$151.8M | -166.8% |
| FY2023 | $106.3M | -$46.1M | -43.4% |
| FY2022 | $97.9M | -$93.2M | -95.1% |
| FY2021 | $130.6M | -$57.3M | -43.9% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 27, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Earnings
Other Coverage
October 4, 2026
Weekly Deals
Micro-cap deals: Lifecore signs cash-and-CVR buyout
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
September 15, 2026
Theme Survey
Torrid Quantifies China Exit as Tariff Refund Uncertainty Spreads
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back
June 8, 2026
Deals
Standard BioTools to Buy Treeline Biosciences in $460 Million All-Stock Deal
Micro-cap deals: Lifecore signs cash-and-CVR buyout
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
September 15, 2026
Theme Survey
Torrid Quantifies China Exit as Tariff Refund Uncertainty Spreads
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back
June 8, 2026
Deals
Standard BioTools to Buy Treeline Biosciences in $460 Million All-Stock Deal